Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.

Authors :: Wallach, Joshua D.
Egilman, Alexander C.
Dhruva, Sanket S.
McCarthy, Margaret E.
Miller, Jennifer E.
Woloshin, Steven
Schwartz, Lisa M.
Ross, Joseph S.
Source :: BMJ: British Medical Journal; 6/2/2018, Vol. 361 Issue 8155, pk2031-11, 11p, 5 Charts, 1 Graph
Publication Year :: 2018

Subjects :: BIOLOGICAL products
CLINICAL trials
CLINICAL drug trials
EXPERIMENTAL design
LONGITUDINAL method
PHARMACY information services
PUBLISHING
DRUG approval
SECONDARY analysis
CLINICAL trial registries
TREATMENT effectiveness
CROSS-sectional method

Full Text Access

Tools